Do low TB prevalence and lack of BCG Vaccinations Contribute to Emergence of Multisystem Inflammatory Syndrome in Children?

Tareef Fadhil Raham
Consultant pediatrician Al-Elwyia Pediatrics Teaching Hospital Baghdad
tareeffadhil@yahoo.com
+9647901584338

Abstract

Background: Emergence of new multisystem inflammatory syndrome in children (MIS-C) is thought to be associated with COVID-19 pandemic. Covid-19 morbidity and mortality variances among countries have been suggested by previous works to be influenced by BCG and previous latent TB infection (which is reflected by TB prevalence) possibly through inducing heterogeneous immunity against SARS-CoV-2.

Aim: To examine influence of BCG status and TB prevalence on variances among countries which report new multisystem inflammatory syndrome in children (MIS-C).

Methods: We choose all countries which report MIS-C till 23/6/2020, number of cases for each 10 million inhabitants was examined among 3 categories of countries classified according to BCG program status. TB prevalence, MIS-C no. / 10 million (M) population and Covid- 19 deaths/M are taken as markers. Receiver operation characteristic - (ROC) curve, with some relative indicators such as (sensitivity and specificity rates), estimation area of trade - off between sensitivity and specificity, and cutoff points are used with different studied markers for discriminating different three pairs of countries (which have different BCG practices).

Results: MIS-C No/10 M inhabitants in countries never gave BCG vaccination versus (vs) countries currently give vaccine shows area under ROC- curve equal to 0.000 with a symbiotic significant of 0.034 and (95% CI interval of 0.000-0.000) also MIS-C No/10 M inhabitants in countries not currently give BCG vaccination (with previous mass vaccination programs) vs countries currently give mass vaccination shows area under ROC- curve equal to 0.094 with a symbiotic significant of 0.027and (95% CI interval of 0.000 -0.280).

Important not significant finding MIS-C No/10 M inhabitants in countries never gave BCG vaccination vs countries not currently give vaccine shows area under ROC- curve equal to 0.583 with a symbiotic significant of 0.683 and (95% CI interval of 0.074-0.759).

COVID-19 deaths / M inhabitants in countries never gave BCG vaccination vs countries currently give vaccine show area under ROC- curve equal to 0.083 with a symbiotic informative and reportable value of 0.077 and (95% CI interval of 0.000-0.309 also COVID-19 deaths/ M inhabitants in countries not currently give BCG vaccination vs countries currently giving vaccine show area under ROC- curve equal to 0.188 with a symbiotic informative reportable value of 0.089 and (95% CI interval of 0.000-0.452).

Important finding is the not significant association of COVID-19 deaths /M inhabitants with countries never gave BCG vaccination vs countries not currently giving vaccine area under ROC- curve equal to 0.417 with a symbiotic significant of 0.683 and (95% CI interval of 0.078 - 0.755).

Regarding TB prevalence marker or discriminator the areas under curve were informative and reportable and too generating with the leftover markers in all 3 pairs of countries signifying inverse relations with covide-19 mortality and MIS-C no.

Conclusions: BCG vaccinations and high TB prevalence are found to be related to decrease MIS-C no. and COVID-19 deaths this might explain variances among countries worldwide. Further studies to confirm this relation and to confirm possible similar relations in Kawasaki disease(KD) or KD like illnesses in previous epidemics is recommended. Review of TB programs and consolidation of BCG programs might be considered urgently.

Key words: Covid-19, SARS-CoV-2, Kawasaki disease, Kawasaki disease shock syndrome

No conflicts of interests

No funding received

Introduction

In April 2020, reports emerged from the United Kingdom of a presentations in children similar to incomplete Kawasaki disease (KD) or toxic shock syndrome[1,2,3]. In Italy, approximately 10 suspected Kawasaki-like disease cases have been recorded since 1

January 2020, eight of which were reclassified as new Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection in children (PIMS-TS)[4] or multisystem inflammatory syndrome in children (MIS-C) or paediatric hyper inflammatory syndrome, or paediatric hyper inflammatory shock[1]which is hyper inflammatory syndrome with multiorgan involvement have some features similar to those of Kawasaki disease and toxic shock syndrome (KDSS)[5]. MIS-C cases also been reported since then in USA and countries in Europe. Classical KD with concurrent COVID-19 also have been reported[6].

(KD) is an acute febrile systemic vasculitis that predominantly occurs in children younger than 5 years of age and the most common acquired heart disease during childhood in most industrialized countries[7]. The annual incidence of KD is highest in Japan, with more than 300 per 100□000 children aged 4 years or younger affected[8], compared with 25 per 100□000 children aged 5 years or younger in North America[9]and is rarely reported in sub-Saharan Africa[10]. Although KD is less common in western countries KD shock syndrome (KDSS) a rare form of KD has a higher incidence in these countries (2.60 to 6.95%)[11,12 ,13, 14] ,compared with Asian countries like Taiwan which reported lower incidence rate (1.45%)[15].

KDSS is often associated with myocarditis and requires critical care support during the acute phase of illness KDSS might mimic toxic shock syndrome[121]. The severity of inflammation in KD is reflected by inflammatory parameters; thus, laboratory findings are helpful for diagnosing incomplete KD just like MIS-C. A child is considered to have incomplete KD when there are fewer than 4 clinical features in the presence of fever[1]. "Atypical KD" should be used in the presence of an unusual or odd manifestation of KD (e.g., nephritis or central nervous system complication)[16]. Incomplete KD is considered to be a mild form of KD.

A high level of circulating pro-inflammatory cytokines might contribute to the distributive component of shock. Indeed, KDD has been found associated with high levels of IL-6, , and procalicitonin[12]. Patient with MIS-C also high levels of inflammatory markers, including procalcitonin, and serum interleukin 6[17]. Furthermore elevation of inflammatory markers (cytokines) has been previously demonstrated in inflammatory state for multiple

conditions[18]including cytokine storms. Cytokine storm denotes a hyperactive immune response characterized by the release of interferons, interleukins, tumor-necrosis factors, chemokines, and several other mediators. Cytokine storms can be caused by a number of infectious, especially viral respiratory infections such as H5N1,H1N1 influenze and SARS-CoV2[19,20] Other causative agents include the Epstein-Barr virus, cytomegalovirus[21]. Likewise in KD circumstantial evidence points to an infectious cause[22]. In the past 20 years, viruses of the coronavirus family have been proposed as possibly implicated in the pathogenesis of Kawasaki disease in small percentage[23,24].

The case definition of MIS-C was regarded by some experts as quite broad and overlaps with Kawasaki disease,[25]. On the contrary other experts are concerned that current diagnostic criteria may not capture the true scope of the problem[26].

Cardiac manifestations in MIS-C might mimic Kawasaki or Kawasaki shock syndrome and include myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities other clinical features may overlap. Reactivation of the Bacillus Calmette–Guérin (BCG) injection site has been listed by the American Heart Association as a significant finding among the diagnostic guidelines for KD[27]. Such finding might account to 50%of patients[28,29] BCG reactivation is thought to happen due to suggested cross reactivity of mycobacterial Heat Shock Protein 65 (HSP65) and the human homologue HSP63. Furthermore, cross immune heterogenecity was suggested between BCG and certain viral diseases since BCG induces trained immunity through expressing heterologous antigens of different pathogens which have been developed and tested since 1991[30]. The epidemiological studies have already show associations of implementing mass BCG vaccination and TB prevalence status with reduced severity of COVID-19 disease[31,32]. Epidemiological studies are lacking regarding role of BCG or latent TB protection effect on incidence of MIS-C or KD including KDSS. This study is the first in this aspect looking for MIS-C incidence in relation to TB prevalence status and COVID-19 deaths in different countries classified according to BCG vaccination status and will address disparities raised regarding variances in incidence of MIS-C and COVID-19 deaths rates among countries.

This study also discusses possible relation of KD or KD like illnesses with previous pandemics according to various TB prevalence of some countries.

Material and Methods

Data regarding to MIS-C collected till 23/6/2010 in all countries which register MIS. Then COVID -19 deaths/Million registered as it appeared on public data accessed on 2/7/2020. Countries BCG practices were put in three different groups:

1-No vaccination at all and no previous BCG

2-No current vaccination but with previous vaccination program (countries which ceased BCG vaccinations previously), and

3- Currently giving mass BCG vaccine through national program.

Total countries were 15, they were distributed among that groups status as shown in table No. (1).

COVID -19 mortality, data TB prevalence data, and population data are obtained from publically published data. BCG data are obtained from publically available WHO data and various references.

Receiver operation characteristic - (ROC) curve, as well as some relative indicators such as (sensitivity and specificity rates), and cutoff points are used for discriminating different three categories of countries (which have different BCG practices). Discrimination of these categories done through studied markers. All statistical operations were performed through using the ready-made statistical package SPSS, ver. 22.

Patient and public involvement statement:

It was not appropriate or possible to involve patients or the public in this work given that we used general practice level summated data and related publically published morbidity and mortality statistics. Patients were not involved

Results and Findings:

Table No. (1): MIS-C No./10M, COVID -19 deaths/Million versus BCG practice group of countries

Countries	MIS cases /10M. pop.	Year Stopped mass BCG vaccination	COVID deaths /M.	TB Prevalence
1-No vaccination at all no previous BCG				
Canada	3.179	0/0	228	6
Italy	1.654	0/0	575	7
United State	5.619	0/0	395	3
Mean	3.484	-	399.3	5.3

2-No current vaccination (previous vaccination)				
Austria	**1.110**	**1990**	**78**	**7**
France	**19.15**	**2007**	**457**	**9**
Germany	**0.596**	**1998**	**108**	**7**
Luxembourg	**79.875**	**2005**	**176**	**8**
Spain	**4.705**	**1981**	**607**	**9**
Sweden	**2.971**	**1975**	**532**	**6**
Switzerland	**3.466**	**1987**	**227**	**6**
United kingdom	**5.892**	**2005**	**647**	**8**
Mean	**14.29**	**-**	**354**	**7.5**
3-Currently giving BCG vaccine				
Greece	**0.959**	**Not stopped**	**18**	**5**
Portugal	**0.981**	**Not stopped**	**155**	**24**
Peru	**0.303**	**Not stopped**	**299**	**123**
Russian Federation	**0.891**	**Not stopped**	**66**	**54**
Mean	**0.78**	**-**	**134.5**	**51.5**

MIS-C: Multisystem Inflammatory Syndrome in children

Table 1 shows collected data for the study sample in terms of country no. of MIS-C cases, BCG status, COVID -19 deaths and TB prevalence.

Group 1 (countries with no vaccination at all and no previous BCG national programs) shows highest mean value for COVID-19 deaths/M inhabitant and lowest for TB prevalence.

Group 3 (countries currently giving BCG vaccine) shows lowest MIS-C no./10 M and lowest COVID-19 mortality and highest TB prevalence.

Group 2 No current vaccination (previous vaccination) group shows highest MIS-C and other parameters were in between.

Table No. (2) and fig (1) show estimated area of trade - off between sensitivity and specificity of markers through plotting sensitivity against a complement specificity outcome to examine the trade - off, which is called (ROC) curve, table 2 also show a significant level for testing area under the guideline of fifty percent, with 95% confidence interval of all probable combinations of pairs of countries and were as follows:

1- Pair of countries with no vaccination program at all (x axis) & no current vaccination program but have previous vaccination program (y axis):

The common think in this pair is that both groups had no vaccination programs at this time whether had previous history of vaccinations or not.

2- Pair of countries with never gave BCG vaccination program (x axis) & those with currently giving BCG vaccination (y axis).

3-Pair of countries with currently no vaccination (ceased vaccination program) (x axis) & currently vaccinated (y axis). The common think in this pair is having vaccination whether in the past or at the current time.

Findings are as shown in table 2 and fig. 1 : MIS-C no./10 M inhabitants in countries never gave BCG vaccination vs countries currently giving vaccine (pair 2) shows area under ROC- curve equal to 0.000 with a symbiotic significant of 0.000 and (95% CI interval of 0.000-0.000) also MIS-C No/10 M inhabitants in countries not currently give BCG vaccination(ceased mass vaccination programs) vs countries currently give mass vaccination (pair 3) shows area under ROC- curve equal to 0.094 with a symbiotic significant of 0.027and (95% CI interval of 0.000 -0.280).

Important not significant finding is that MIS-C no./10 M inhabitants in countries never gave BCG vaccination vs countries not currently giving vaccine (1st pair) shows area under ROC- curve equal to 0.583 with a symbiotic significant of 0.683 and (95% CI interval of 0.074-0.759). MIS-C no. is a good discriminator in a significant association when countries not currently giving vaccine are in the 3d pair of countries (i.e. with countries currently given BCG vaccine) and not in 1st pair (i.e. with countries never gave national BCG vaccination).

COVID-19 deaths / M inhabitants in countries never gave BCG vaccination vs countries currently giving vaccine (pair 2) show area under ROC- curve equal to 0.083 with a symbiotic informative and reportable value of 0.077 and (95% CI interval of 0.000-0.309 also COVID-19 deaths / M inhabitants in countries not currently giving BCG vaccination vs countries currently giving vaccine(3d pair) show area under ROC- curve equal to 0.188 with a symbiotic informative reportable value of 0.089 and (95% CI interval of 0.000-0.452)

Important finding is the non-significant association of COVID-19 deaths no. /M inhabitants in countries never gave BCG vaccination vs countries not currently give vaccine (1st pair) which shows area under ROC- curve equal to 0.417 with a symbiotic significant of 0.683

and (95% CI interval of 0.078 - 0.755). COVID-19 deaths are a good discriminator in a significant association when countries not currently give vaccine are in third pair of countries (i.e. with countries currently given vaccine) and not in 1st pair (i.e. with countries never gave BCG vaccine in their national programs.

Regarding TB prevalence marker or discriminator the areas under curve were informative and reportable and too generating with the leftover markers in all pairs and were 0.833 with 59% CI of 0.572-0.755 in pair one and 0.833 with 95% CI interval of 0.5- 0.500 and 0.750 with 95% CI interval of 0.326-1.174 in pairs 2 and 3 respectively. These signifying inverse relations with COVID-19 mortality and MIS-C no. curves. The informative reportable asymptotic values were 0.102,0.157 and 0.174 for 3 pairs respectively.

Table: (2): Relationships among a diseased groups & controlled for all probable combinations of Disclusion time test in different parameters

Group's Combinations	Parameters	Area	Std. Error	Asymp. Sig.	Asymp. 95% C.I.	
					L.b.	U.b.
I X II	MIS cases /10M pop.	0.583	0.175	0.683	0.241	0.926
	COVID-19 Deaths /M.	0.417	0.173	0.683	0.078	0.755
	TB Prevalence	0.833	0.133	0.102	0.572	1.094
I X III	MIS cases /10M pop.	0.000	0.000	0.034	0.000	0.000
	COVID-19 Deaths /M.	0.083	0.115	0.077	0.000	0.309
	TB Prevalence	0.833	0.170	0.157	0.500	1.167
II X III	MIS cases /10M pop.	0.094	0.095	0.027	0.000	0.280
	COVID -19 Deaths /M.	0.188	0.135	0.089	0.000	0.452
	TB Prevalence	0.750	0.217	0.174	0.326	1.174

(*) S: Significant at P< 0.05; NS: Non Significant at P> 0.05, informative reportable p value>0.05 if close to (but does not reach) 0.05 and confirmed by minimum confidence interval (Robert J. Nordness, "Epidemiology and Biostatistics Secrets", MOSBY ELSEVIER, 1600 John F. Kennedy Boulevard, Suite 1800 Philadelphia, PA 19103-2899, P156, 2006),I: No vaccinated at all; II: No currently vaccinated; III: Currently giving vaccination.

Figure (1) represented graphically of ROC Curve plots for studied markers in relative with BCG practices in pair's combinations in light of different three categories conditions.



In figure (1) TB prevalence marker or discriminator looks too generating with the leftover markers in all 3 pairs.

In order to create a cut-off points for the markers searched between the three pairs of classifiers in relation with BCG practices, and some screening tests such as sensitivity, and specificity rates are presented in table No. (3).

Table: (3): Estimation of sensitivity, specificity rates and construction a cutoff points among different three categories of BCG vaccine due to studied markers

Group's Combinations ((Pairs))	Parameters	Cutoff Points	Sensitivity	Specificity
I X II	MIS cases /10M pop.	3.323	0.625	0.667
	COVID-19 Deaths /M.	591.0	0.250	1.000
	TB Prevalence	7.500	0.500	1.000
I X III	MIS cases /10M pop.	0.597	0.750	0.000
	Covid Deaths /M.	42.000	0.750	0.000
	TB Prevalence	15.50	0.750	1.000
II X III	MIS cases /10M pop.	49.513	0.000	0.875

	COVID -19Deaths /M.	627. 0	0.000	0.875
	TB Prevalence	16.50	0.750	1.000

(*) S: Significant at P< 0.05; NS: Non Significant at P> 0.05
I: No vaccinated at all; II: No currently vaccinated; III: Currently giving vaccination.

Results show that MIS-C cutoff points seem to be inconsistent for the three pairs with too increase for the third pair and lowest in 1st pair.

It is clear that TB prevalence cutoff point is more in 3d pair followed by 2nd pair both of these pairs have countries with current BCG vaccination programs.

Discussion

According to this study MIS-C and Covid-19 deaths incidences are low in countries currently give BCG vaccine. There is partial effect within countries with previous vaccination programs. Countries never gave BCG vaccine being most severely affected.

Although there are significant associations these results still possibly subjected to potential confounding factors because study is done in mid of COVID-19 pandemic. Another possibility is that MIS-C is subjected to under registration and under reporting among different countries. Anyhow our findings consolidate previous literatures which suggest influence of BCG and TB prevalence status in lowering COVID-19 [32,33], mortality.

It is obvious that MIS-C was first thought to be KD or KDSS [4]. After developing diagnostic criteria for MIS-C, some believe that these criteria are broad,[25] others believe these criteria are narrow[26].

Till 23/6/2020 nine countries reported MIS-C, even though many other countries continue to report further. News of confirmed or suspected cases has since emerged from several other countries[34,35,36,37,38,39].

The first patient with KD was reported in 1961 then , 50 patients published in 1967 by Dr. Tomisaku Kawasaki[40]. Incidence of KD (per 100,000 less than 5-year-olds)[41] is 308 in Japan in 2014[42],194.7-217.2 in South Korea in 2014[43,44], 71.9.03 -116.6 in China in 2010-2014[45]. Recently, greater numbers of countries report incomplete KD cases[46].

During 1918 pandemic there were no reports for KD or KD like disease condition. Since that time literature research on the impact of Spanish influenza does indicate that the Chinese people survived much better than people in the USA and Europe[47]. There is no

evidence of KD like condition in China apart from viral erythema misdiagnosed as scarlet fever reported in some patients in China[47].

In Europe and USA it seems that the epidemic was started earlier than 1918[48]. There was widespread of measles epidemic by early October 1917 and continuing into 1918 according to medical reports[49]. At same time there were increases in scarlet fever and in measles case-fatalities. Measles produced the highest infection rates in 97 years of continuous military surveillance[50] and extreme case-fatality from aggressive bronchopneumonias and other complications[49]. Furthermore, some of the reported deaths with primary pneumonia or empyema without measles [49]. It seems that skin rashes were not reported as a sign of Spanish flu in affected persons in USA unlike in china. After KD becomes well known disease, differentiation between KD and measles might be difficult[51]. Furthermore, differentiation was impossible in 1917-1918 since KD is not yet known, added to that there were no lab facilities to differentiate between 2 diseases.

Interstitial bronchopneumonia was used to describe 1917 measles and1918 influenza autopsy findings[49, 52,53]. Evidences pointing that the Spanish influenza began in USA , France , UK and Austria before 1918 [54, 55, 56 , 57,58, 59].

Tuberculosis mortality was in decline in the USA since at least the mid-nineteenth century and continued to decline even if the 1918 pandemic had not occurred[60].

In Japan large-scale influenza epidemics have occurred in the past, including the Spanish flu during 1918–1920, Asian flu during 1957–1958, Hong Kong flu during 1968–1969, and 2009 H1N1 pandemic during 2009–2010. Influenza outbreak in 1957 is caused by (H2N2) and the quite extensive outbreaks in 1962 and 1965 were due to drift variants[61]. Furthermore 13 outbreaks of swine influenza were recognized in Japan from 1978 – 1979[62]. Influenza type B viruses were also associated with increased morbidity widespread illness in 1982[63]. The 1986-87 influenza epidemic was caused by influenza A(H1N1) variant first isolated in China, Malaysia, Japan, and Singapore during 1986[64]. It seems that temporally associated with 4 previous out brakes, three large KD epidemics were recorded in Japan—in 1979, 1982, and In 1986 in addition to the first reported cases by Tomisaku Kawasaki in 1967[40].

In 1953, Japan was highly endemic with TB. By developments in TB treatment,[65,66] , and giving mass BCG vaccinations since 1948 till now, (boosters were given also before 2003), the mortality rate from TB dropped sharply [66].

The reported annual incidence rates of KD per 100,000 children aged 0 to 4 years in Japan was 206.2 in 2009 and 239.6 in 2010, the 2010 rate was the highest ever reported before. The influenza epidemic in 2009, (H1N1) was suggested for this increase in incidence[67].

TB prevalence in japan was 17 in 2011[68]decreased to 14 in 2018[69], while KD incidence increased to 308 in 2014. It is possibly that decreasing in TB prevalence might be a factor in emerging of KD (in the presence of BCG national vaccination program) as noticed in Japan, while it seems that decreasing TB prevalence might be a factor in KDSS or MIS-C in countries with no current mass BCG vaccinations. This should be confirmed by further studies.

In USA a wide outbreak of KD , apparently the 1st in the USA, occurred in Hawaii in the first half of 1978. Isolates of H1N1 in 50 states in 1977 were reported with new variant of H1N1 reported in few states including Hawaii[70]. During 1984 - 1985, 10 outbreaks of (KS) outbreaks occurred in 10 states and the district of Columbia[71 ,72].

In South Korea the incidence rates of KD just after 2009 influenza pandemic increased from 115.4 in 2009 to 134.4 per 100,000 children in 2011[43,44]. This furtherly increased to 170.9, 194.9 and 194.7 in 2012, 2013 and 2014, respectively[44].TB prevalence in south Korea was 80 in 2011 decreased to 66 in 2018[73]. Compared to Japan, South Korea have lesser incidence of KD and higher TB prevalence since South Korea start BCG at late times in 70s and stopping boosters in 2007[74].

In China: the start and peak of KD epidemics are in 1979, 1982, and 1986, these out brakes are coincidental to Japan's for mentioned peaks of KD , furthermore there are seasonal outbreaks between 1987-2010 [75]. In general, KD incidence is low in China compared to Japan with trends to increase in recent years. The mean incidence in Sichuan Province (2003-2007) was 7.1[76]and rising from 26 in 1994 to 39 in 2000 and to 74 in 2011 in Hong Kong[77]. Furthermore, the incidence is as high as 116.6 in 2014 in Beijing[45].

The "flu" of 1979(H2 N2) originated in fact in China in 1977[78], a new influenza A(H1N1) virus was isolated in China in 1982[79], another new variant of H1N1 was isolated for first time in China as mentioned in 1986. TB prevalence in China was 134.27 in 1990 and 137.93 in 2015 per 100,000 persons[80] and decreased to 61 in 2018[69].

In Europe, the epidemiology of KD ranges from 3.6 to 15.2/100,000[81] but (KDSS) has a higher incidence in these countries[13], compared with Asian countries, the real cause for high incidence of KDSS in western countries is unknown yet.

BCG unlike natural infection gives protection to 50%-60 %[82] of target population against TB and has immunological heterogeneous effect against some other pathogens[30]. Clinical trials are in progress to establish relations to prevention of SARS-CoV-2 infection.

The temporal associations of KD out brakes in different countries with concurrent virus out brakes and relations of KD to low TB prevalence are of possible concern and this points to probable causation relation. Furthermore, causation might be back to 1917-1918 pandemic or even before. Furtherly possible relation of lack of BCG with KDSS or to MIS-C is of further concern.

Conclusions: This study shows a significant relation between BCG and both of incidence of MIS-C and COVID – 19 deaths, also between TB prevalence and both of incidence of MIS-C and COVID-19 deaths.

Recommendations:

Controlled clinical trials are required to confirm causation of TB prevalence and BCG status to MIS-C or to Kawasaki like spectrum of diseases in general.

Ethics and dissemination:

Ethical permission is not necessary as this study analyzed publically published data and patients were not involved. There is no conflict of interest.

There is no funding received.

Acknowledgment:

I am deeply grateful to Emeritus Professor Abdulkhaleq Abduljabbar Ali Ghalib Al-Naqeeb, Ph.D. in the Philosophy of Statistical Sciences at the Medical & Health Technology college, Baghdad-Iraq, for his assistance and support in data analysis, interpretations of finding results, and revision and displaying the paper.

[1] Son, MBF , Friedman,K .Coronavirus disease 2019 (COVID-19): Multisystem inflammatory syndrome in children. *UPTODATE*.

https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-multisystem-inflammatory-syndrome-in-children?sectionName=CASE%20DEFINITION&topicRef=2841&anchor=H1928154455&source=see_link

Accessed: July 15,2020

[2] Riphagen S, Gomez X, Gonzalez-Martinez C . Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*. 2020;395(10237):1607-1608. doi:10.1016/S0140-6736(20)31094-1

[3] PICS, 2020. *Paediatric Intensive Care Society (PICS) Statement: Increased number of reported cases of novel presentation of multi system inflammatory disease.* news
https://picsociety.uk/wp-content/uploads/2020/04/PICS-statement-re-novel-KD-C19-presentation-v2-27042020.pdf
Accessed: July 15, 2020

[4] European Centre for Disease Prevention and Control Pediatric. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. May 2020
Accessed : July 16,2020 (https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment. opens in new tab).

[5] WHO. *Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 . Scientific Brief*. News room, detail .15 May 2020

https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19

Accessed: July 15,2020

[6] Jones VG, Mills M, Suarez D, Hogan CA , Yeh D, Segal JB et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. *Hosp Pediatr*. 2020;10(6):537-540. doi:10.1542/hpeds.2020-0123

[7] Wood LE, Tulloh RM. Kawasaki disease in children. *Heart*. 2009;95(10):787-792. doi:10.1136/hrt.2008.143669

[8] Makino N, Nakamura Y, Yashiro M, Kosami K, Matsubara Y, Ae R, Aoyama Y, *et al.* Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int. 2019 Apr;61(4):397-403. doi: 10.1111/ped.13809. Epub 2019 Apr 16. PMID: 30786118.

9 Son MBF, Newburger JW. Kawasaki Disease. *Pediatr Rev*. 2018 Feb. 39 (2):78-90. [Medline].

[10] Noorani M, Lakhani N. Kawasaki disease: two case reports from the Aga Khan Hospital, Dar es Salaam-

[11]Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, Watson VE, Best BM, Burns JC. Recognition of a Kawasaki disease shock syndrome. *Pediatrics*. 2009 May;123(5):e783-9. doi: 10.1542/peds.2008-1871. PMID: 19403470; PMCID: PMC2848476.

[12] Li Y, Zheng Q, Zou L, Wu J, Guo L, Teng L, *et al*. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. *Pediatr Rheumatol Online J*. 2019 Jan 5;17(1):1. doi: 10.1186/s12969-018-0303-4. PMID: 30611297; PMCID: PMC6321686.

[13] Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glodé MP. Kawasaki disease in a pediatric intensive care unit: a case-control study. *Pediatrics*. 2008;122(4):e786-e790. doi:10.1542/peds.2008-1275

[14] Gamez-Gonzalez LB, Murata C, Munoz-Ramirez M, Yamazaki-Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. *Eur J Pediatr.* 2013;172(3):337–342.

[15] Lin MT, Fu CM, Huang SK, Huang SC, Wu MH. Population-based study of Kawasaki disease shock syndrome in Taiwan. *Pediatr Infect Dis J. 2013 Dec; 32(12):1384-6.*

[16] Thapa R, Chakrabartty S. Atypical Kawasaki disease with remarkable paucity of signs and symptoms. *Rheumatol Int*. 2009;29(9):1095–6.

[17] **Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, *etal*. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.*BMJ* : 2020; 369 doi: https://doi.org/10.1136/bmj.m2094 (Published 03 June 2020)**

[18] **Toshio Tanaka, Masashi Narazaki,and Tadamitsu Kishimoto. IL-6 in Inflammation, Immunity, and Disease. *Cold Spring Harb Perspect Biol*. 2014 ; 6(10): a016295.**

[19] **Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV. Current and future developments in the treatment of virus-induced hypercytokinemia. *Future Med Chem*. 2017;9(2):169-178. doi:10.4155/fmc-2016-0181**

[20] **Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cellular & Molecular Immunology. 2016 Jan;13(1):3-10. DOI: 10.1038/cmi.2015.74.**

[21] **Tisoncik JR, Korth MJ, Simmons CP, *et al*. Into the eye of the cytokine storm. Microbiology and Molecular Biology Reviews : MMBR. 2012 Mar;76(1):16-32. DOI: 10.1128/mmbr.05015-11.**

[22] **Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Monthly observation of the number of patients with Kawasaki disease and its incidence rates in Japan: chronological and geographical observation from nationwide surveys. *J Epidemiol*. 2008;18(6):273-279. doi:10.2188/jea.je2008030**

23 Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. *J Infect Dis*. 2005;191(4):499-502. doi:10.1086/428291

24 Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent Respiratory Viruses and Kawasaki Disease. *Pediatrics*. 2015;136(3):e609-e614. doi:10.1542/peds.2015-0950

[25] **Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children [published online ahead of print, 2020 Jun 16]. *Nat Rev Immunol*. 2020;1-2. doi:10.1038/s41577-020-0367-5**

[26] **Phillips D. Diagnostic Criteria May Miss Some MIS-C Cases, Experts Say. Medscape.**

https://www.medscape.com/viewarticle/933303?nlid=136249_5141&src=WNL_mdplsfeat_200707_mscpedit_peds&uac=114663BT&spon=9&impID=2450715&faf=1

Accessed: July 02, 2020

[27]**Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, *et al* . Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation*. 2004 Oct 26;110(17):2747-71. doi: 10.1161/01.CIR.0000145143.19711.78. PMID: 15505111.**

[28] **Rezai MS, Shahmohammadi *S*. Erythema at BCG Inoculation Site in Kawasaki Disease Patients. *Mater Sociomed.* 2014 Aug; 26(4):256-60.**

[29] **Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site. *Pediatr Infect Dis J*. 2010;29(5):430-433. doi:10.1097/INF.0b013e3181cacede**

[30] **Camila C, Ayleen F , Angello RD, *et al*. BCG-induced cross-protection and development of trained Immunity: implication for vaccine design. *Frontiers Immunology* . 2019; 10 :2806. doi:10.3389/fimmu.2019.02806**

[31] **BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Luis E. Escobar, Alvaro Molina-Cruz, Carolina Barillas-Mury**

Proceedings of the National Academy of Sciences. Jul 2020, 202008410; DOI: 10.1073/pnas.2008410117

[32] TF,Raham. TB Prevalence Influence on Covid-19 Mortality. *International Journal of Psychosocial Rehabilitation.* 24(10) ;2020 : 3679- 3690

[33] Soliman R, Brassey J , Plüddemann A, *etal*. Does BCG vaccination protect against acute respiratory infections and COVID-19 ?.A rapid review of current evidence . CEBM . 24/4/ 2020. https://www.cebm.net/covid-19/does-bcg-vaccination-protect-against-acute-respiratory-infections-and-covid-19-a-rapid-review-of-current-evidence. Accessed on 1/7/2020

[34] Семенова, Мария (17 June 2020). "В Москве умер первый ребенок из-за новой болезни, вызванной COVID-19" (in Russian). *RIA Novosti*. Retrieved 16 july 2020.

[35] Smith B. Indiana Has First Case of Children's Inflammatory Syndrome Linked to COVID-19. *Lake Shore Public Radio*. May 18 ,2020 https://www.lakeshorepublicradio.org/post/indiana-has-first-case-childrens-inflammatory-syndrome-linked-covid-19#stream/0

[36] Umer D, Ahmed T .Post-coronavirus Kawasaki-like inflammatory syndrome reported in eight children in Lahore. *Samaa TV*. (8 July 2020). Accessed : 9 July 2020

[37] Bahrami A, Vafapour M, Moazzami B, Rezaei N. Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: First case from Iran [published online ahead of print, 2020 Jul 8]. *J Paediatr Child Health*. 2020;10.1111/jpc.15048. doi:10.1111/jpc.15048

[38] Jaffe- Hofmfman M.What is the new inflammatory syndrome infecting children after COVID-19? Jerusalem *Post*. May 17, 2020

[39] Saada H. "Algeria registers first case of Kawasaki disease". *DZ Breaking* retrieved on 18/7/202

[40] Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. *Arerugi*. 1967; 16:178–222.

[41] Kim G B. Reality of Kawasaki disease epidemiology. *Korean J Pediatr*. 2019 Aug; 62(8): 292–296.Published online 2019 Jul 9. doi: 10.3345/kjp.2019.00157.

[42] Makino N, Nakamura Y, Yashiro M, Sano T, Ae R, Kosami K ,*et al*. Epidemiological observations of Kawasaki disease in Japan, 2013-2014. *Pediatr Int*. 2018 Jun;60(6):581-587. doi: 10.1111/ped.13544. PMID: 29498791.

[43] Ha S, Seo GH, Kim KY, Kim DS. Epidemiologic Study on Kawasaki Disease in Korea, 2007-2014: Based on Health Insurance Review & Assessment Service Claims. *J Korean Med Sci*. 2016;31(9):1445-1449. doi:10.3346/jkms.2016.31.9.1445

[44] Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL, *et al*. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. *Pediatr Infect Dis J*. 2017 May;36(5) 482-485. doi:10.1097/inf.0000000000001474. PMID: 27997519.

[45] Chen JJ, Ma XJ, Liu F, Yan WL, Huang MR, Huang M, *et al*. Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012. *Pediatr Infect Dis J*. 2016;35(1):7-12. doi:10.1097/INF.0000000000000914

[46] Kim SH, Kim KH, Kim DS. Clinical characteristics of Kawasaki disease according to age at diagnosis. *Indian Pediatr*. 2009;46(7):585-590.

[47] Cheng KF, Leung PC. What happened in China during the 1918 influenza pandemic? *Int J Infect Dis.* 2007;11(4) 360-364. doi:10.1016/j.ijid.2006.

[48] Eugene L. Opie, Allen W. Freeman, Francis G. Blake, James C. Small and Thomas M. Rivers. Pneumonia at Camp Funston. Report to the Surgeon-General. *Journal of the American Medical Association* 72(2), January 1919, pp. 108-116.

[49] Morens DM, Taubenberger JK. A forgotten epidemic that changed medicine: measles in the US Army, 1917-18. *Lancet Infect Dis*. 2015;15(7):852-861. doi:10.1016/S1473-3099(15)00109-7

[50] Love AG. A brief summary of the viral statistics of the US Army during the World War. *Mil Surg* 1922; 51: 139–68.
[51] Rowley AH.Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features. *The Journal of Pediatrics.* Published:June 22, 2020DOI:https://doi.org/10.1016/j.jpeds.2020.06.057

[52] Callendar GR. Pathology of the acute respiratory diseases. I. In camps in the United States. In: Ireland MW, Callendar GR, Coupal JF, eds. *The Medical Department of the United States Army in the World War*. Volume XII. Pathology of the acute respiratory diseases, and of gas gangrene following war wounds. Washington DC: US Government Printing Office, 1929: 7–186.
[53] Cole R, MacCallum WG. Pneumonia at a base hospital. J Am Med Assoc 1918; 70: 1146–56.
[54] Chertow DS , Cai R, Sun J, Grantham J, Taubenberger JK, Morens DM. Influenza Circulation in United States Army Training Camps Before and During the 1918 Influenza Pandemic: Clues to Early Detection of Pandemic Viral Emergence, *Open Forum Infectious Diseases*. 2015:2(2) 2015, ofv021, https://doi.org/10.1093/ofid/ofv021
[55] Vikki Valentine (20 February 2006). "Origins of the 1918 Pandemic: The Case for France". National Public Radio. Accessed from NPR site in 13 July 2020.
https://www.npr.org/templates/story/story.php?storyId=5222069
[56] Connor S (8 January 2000). "Flu epidemic traced to Great War transit camp". *The Guardian*. UK. Accessed from The Guardian site in 16 july 2020.
https://www.theguardian.com/world/2018/sep/09/spanish-flu-pandemic-centenary-first-world-war
[57] Oxford JS. The so-called Great Spanish Influenza Pandemic of 1918 may have originated in France in 1916. *Philos Trans R Soc Lond B Biol Sci*. 2001;356(1416):1857-1859. doi:10.1098/rstb.2001.1012
[58] Oxford JS, Lambkin R, Sefton A, *et al* . A hypothesis: the conjunction of soldiers, gas, pigs, ducks, geese and horses in northern France during the Great War provided the conditions for the emergence of the "Spanish" influenza pandemic of 1918–1919. *Vaccine.* 2005;23:940–945. doi: 10.1016/j.vaccine.2004.06.035

[59] Price-Smith AT (2008). *Contagion and Chaos.* Cambridge, MA: MIT Press. *ISBN 978-0-262-66203-1*.
[60] Noymer A,The 1918 influenza pandemic hastened the decline of tuberculosis in the United States: An age, period, cohort analysis,*Vaccine*, 29, Supplement 2;2011: B38-B41,

[61] Sumi A, Kamo K, Ohtomo N, Mise K, Kobayashi N. Time series analysis of incidence data of influenza in Japan. *J Epidemiol*. 2011;21(1):21-29. doi:10.2188/jea.je20090162

[62]Komadina N, McVernon J, Hall R, Leder K. A historical perspective of influenza A(H1N2) virus. *Emerg Infect Dis*. 2014;20(1):6-12. doi:10.3201/eid2001.121848

[63] CDC (1982). *International Notes Influenza – Worldwide.*MMWR .1982; 31(8): 107

https://www.cdc.gov/mmwr/preview/mmwrhtml/00000217.htm
Accessed :July 1, 2020
[64] CDC. *Antigenic variation of recent influenza A(H1N1) viruses*. MMWR 1986; 35:510-2

[65] Japan International Cooperation Agency (March 2005). Infectious Diseases Control (Tuberculosis, Parasitic Disease, Immunization Programs) in *: Japan's Experiences in Public Health and Medical Systems* . p114

[66] Kim JH, Yim JJ. Achievements in and Challenges of Tuberculosis Control in South Korea. *Emerg Infect Dis*. 2015;21(11):1913-1920. doi:10.3201/eid2111.141894

[67] Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, *et al*. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. *J Epidemiol*. 2012;22(3):216-21. doi: 10.2188/jea.je20110126. Epub 2012 Mar 10. PMID: 22447211; PMCID: PMC3798622.

[68]A database of global vaccination policies and practices.*PRACTICES .The world BCG atlas* . 2nd edition .2017

http://bcgatlas.org/index.php
accessed : July 28 ,2020

[69] WHO. *Tuberculosis country profiles*

https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&iso2=%22CN%22&main_tabs=%22est_tab%22
accessed : July 28,2020
[70] CDC 1983. *Influenza surveillance report no. 93, August 1977-March 1979*
https://stacks.cdc.gov/view/cdc/289

Accessed :July 1 ,2020

[71] CDC. Multiple Outbreaks of Kawasaki Syndrome -- United States.*MMWR* .1985 ;34(3):33-35.
https://www.cdc.gov/mmwr/preview/mmwrhtml/00000470.htm
Accessed :July 1, 2020

[72] CDC. Current Trends Influenza -- United States, 1983-1984 Season . *MMWR*.1984 ;33(29):417-
https://www.cdc.gov/mmwr/preview/mmwrhtml/00000378.htm

accessed :July 2, 2020

[73] The world bank. *Incidence of tuberculosis (per 100,000 people)*
https://data.worldbank.org/indicator/SH.TBS.INCD
Accessed :July 1,2020

[74]Cho KS. Tuberculosis control in the Republic of Korea. *Epidemiol Health*. 2018;40:e2018036. doi:10.4178/epih.e2018036
[75] Frazer J .Kawasaki disease origin traced to northeast China .*Nature International Weekly Journal of Science*. 19 May 2014

https://www.nature.com/news/kawasaki-disease-origin-traced-to-northeast-china-1.15252#:~:text=Kawasaki%20disease%20could%20be%20the,National%20Academy%20of%20Sciences1.
Accessed: 2/7/2020

[76] Ma XJ, Yu CY, Huang M, Chen SB, Epidemiologic features of Kawasaki disease in Shanghai from 2003 through 2007.Shanghai Kawasaki Research Group.

Chin Med J (Engl). 2010 Oct; 123(19):2629-34.

[77]Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. *Arch Dis Child*. 2015 Nov; 100(11):1084-8.

[78] Kilbourne ED. Influenza-1979. The *American Journal of Medicine*. 1979; 66:371-372

[79] CDC. Influenza – Worldwide. *MMWR*. 1982; 31(36):494-
https://www.cdc.gov/mmwr/preview/mmwrhtml/00001158.htm
accessed : 1/7/2020
[80] Zhu S, Xia L, Yu S, Chen S, Zhang J. The burden and challenges of tuberculosis in China: findings from the Global Burden of Disease Study 2015 [published correction appears in *Sci Rep*. 2018 Jan 24;8(1):1746]. *Sci Rep*. 2017;7(1):14601. Published 2017 Nov 6. doi:10.1038/s41598-017-15024-1
[81] Sánchez-Manubens J, Antón J, Bou R, Iglesias E, *et al.* Kawasaki Disease in Catalonia Working Group Incidence, epidemiology and clinical features of Kawasaki disease in Catalonia, Spain. *Clin Exp Rheumatol.* 2016;34(3 Suppl 97):S139–44.

[82] **Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, *et al*. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics*. 1995 Jul;96(1 Pt 1):29-35. PMID: 7596718.**